Glucotrol
(Glipizide)ApprovedSmall molecule
PfizerGlipizide is used to help control blood sugar levels in people with type 2 diabetes by stimulating the pancreas to release more insulin.[2] Glucotrol is currently approved and in use across 7 indications[4].[1]
Glucotrol is one of 209 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
7
Indications
23
Total Trials
2
Active Trials
208
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Glucotrol
PfizerApproved
Gemzar
GGynecologic Oncology Group
Preclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Meglitinides
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus6 trials
Show 3 more trials
Type 2 Diabetes3 trials
Metformin2 trials
Type 2 Diabetic Patients2 trials
9 more indications
Chronic Kidney Disease1 trial
Coronary Artery Disease1 trial
Diabetes1 trial
Atherosclerosis1 trial
Tics1 trial
Inflammation1 trial
Effect of Exenatide on Liver and Heart Fat and Inflammation
Completed·—·Phase 4·NCT01951651·24 enrolled
Pancreatic Cancer1 trial
Regulatory
FDA Approval Timeline[5]
May 11, 1993
GLUCOTROL
NDA NDA017783
Aug 10, 1999
GLUCOTROL XL
NDA NDA020329
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Glucotrol drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Glipizide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]